EyePoint Pharmaceuticals, Inc. (EYPT) News
Filter EYPT News Items
EYPT News Results
| Date | Symbol | Company | Title | Start | End | Change | POWR Rating | ||
|---|---|---|---|---|---|---|---|---|---|
| Loading, please wait... | |||||||||
EYPT News Highlights
-
404 Page not found Error: Page not found
The requested URL was not found on this server.
-
404 Page not found Error: Page not found
The requested URL was not found on this server.
-
404 Page not found Error: Page not found
The requested URL was not found on this server.
Latest EYPT News From Around the Web
Below are the latest news stories about EYEPOINT PHARMACEUTICALS INC that investors may wish to consider to help them evaluate EYPT as an investment opportunity.
EyePoint Appoints Renowned Retina Specialist and Industry Pioneer Reginald J. Sanders, M.D., FASRS to Board of DirectorsWATERTOWN, Mass., Jan. 08, 2025 (GLOBE NEWSWIRE) -- EyePoint Pharmaceuticals, Inc. (NASDAQ: EYPT), a company committed to developing and commercializing innovative therapeutics to improve the lives of patients with serious retinal diseases, today announced the appointment of Reginald J. Sanders, M.D., FASRS, a distinguished leader in ophthalmology, to its Board of Directors. “I am pleased to welcome Dr. Sanders to EyePoint’s Board,” said Göran Ando, M.D., Chair of the Board of Directors of EyePo |
EyePoint reports inducement grants under NASDAQ listing ruleEyePoint (EYPT) announced that the Company granted non-statutory stock options to new employees as inducement awards outside the Company’s 2023 Long-Term Incentive Plan in accordance with NASDAQ Listing Rule 5635(c)(4). The Company granted stock options to purchase up to an aggregate of 54,600 shares of EyePoint Pharmaceuticals common stock to six new employees. The stock options were granted on December 13, 2024. The grants were approved by the Compensation Committee and made as an inducement m |
EyePoint to Present at the 43rd Annual J.P. Morgan Healthcare ConferenceWATERTOWN, Mass., Dec. 17, 2024 (GLOBE NEWSWIRE) -- EyePoint Pharmaceuticals, Inc. (NASDAQ: EYPT), a company committed to developing and commercializing innovative therapeutics to improve the lives of patients with serious retinal diseases, today announced that Jay S. Duker, M.D., President and Chief Executive Officer of EyePoint Pharmaceuticals will present at the 43rd Annual J.P. Morgan Healthcare Conference in San Francisco on Tuesday, January 14, 2025 at 2:15 p.m. PT/5:15 p.m. ET. A webcast |
EyePoint Pharmaceuticals Reports Inducement Grants Under NASDAQ Listing Rule 5635(c)(4)WATERTOWN, Mass., Dec. 16, 2024 (GLOBE NEWSWIRE) -- EyePoint Pharmaceuticals, Inc. (NASDAQ: EYPT), a company committed to developing and commercializing therapeutics to help improve the lives of patients with serious retinal diseases, today announced that the Company granted non-statutory stock options to new employees as inducement awards outside the Company’s 2023 Long-Term Incentive Plan in accordance with NASDAQ Listing Rule 5635(c)(4). The Company granted stock options to purchase up to an |
EyePoint doses first patient in second Phase 3 LUCIA clinical trialEyePoint (EYPT) Pharmaceuticals announced that the first patient has been dosed in the LUCIA trial, the Company’s second global Phase 3 clinical trial of DURAVYU, formerly EYP-1901, for the treatment of wet age-related macular degeneration. DURAVYU is an investigational sustained delivery therapy delivering patent-protected vorolanib, a selective tyrosine kinase inhibitor formulated in proprietary bioerodible Durasert E(TM) for sustained intraocular delivery. LUGANO and LUCIA are global, randomi |
EyePoint Announces First Patient Dosed in Second Global Phase 3 LUCIA Clinical Trial of DURAVYU™ for the Treatment of Wet Age-Related Macular Degeneration– Topline data for Phase 3 pivotal program anticipated in 2026 – WATERTOWN, Mass., Dec. 04, 2024 (GLOBE NEWSWIRE) -- EyePoint Pharmaceuticals, Inc. (NASDAQ: EYPT), a company committed to developing and commercializing innovative therapeutics to improve the lives of patients with serious retinal diseases, today announced that the first patient has been dosed in the LUCIA trial, the Company’s second global Phase 3 clinical trial of DURAVYU, formerly EYP-1901, for the treatment of wet age-related m |
Wall Street Analysts See a 175.07% Upside in EyePoint Pharmaceuticals (EYPT): Can the Stock Really Move This High?The mean of analysts' price targets for EyePoint Pharmaceuticals (EYPT) points to a 175.1% upside in the stock. While this highly sought-after metric has not proven reasonably effective, strong agreement among analysts in raising earnings estimates does indicate an upside in the stock. |
EyePoint price target lowered to $33 from $38 at BairdBaird lowered the firm’s price target on EyePoint (EYPT) to $33 from $38 and keeps an Outperform rating on the shares. The firm said they reported 3Q24 results and recapped recent progress, including recently reported, unexpectedly positive, interim data in the Phase 2 VERONA study in DME, and the dosing of the first patient in the pivotal LUGANO study in wet AMD. Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>> See Insiders’ Hot Sto |
EyePoint Pharmaceuticals Third Quarter 2024 Earnings: Revenues Beat Expectations, EPS LagsEyePoint Pharmaceuticals ( NASDAQ:EYPT ) Third Quarter 2024 Results Key Financial Results Revenue: US$10.5m (down 31... |
EyePoint Pharmaceuticals (EYPT) Reports Q3 Loss, Lags Revenue EstimatesEyePoint Pharmaceuticals (EYPT) delivered earnings and revenue surprises of -12.50% and 14.79%, respectively, for the quarter ended September 2024. Do the numbers hold clues to what lies ahead for the stock? |